Monthly Prescribing Reference

HealthDay News — Recommendations for the diagnosis and management of severe acquired aplastic anemia are presented in a clinical practice guideline issued by the American Society of Hematology and published online March 24 in Blood Advances.

HealthDay News — One in 4 US adults report using artificial intelligence tools or chatbots for physical or mental health information, according to new research released today from the West Health-Gallup Center on Healthcare in America. Stephen Raynes and Ellyn Maese, from Gallup, conducted the nationally representative survey of more than 5500 US adults from October through December 2025.

Case Study: Explanation: A 17-year-old adolescent presents with a several-month history of recurrent bumps on her forehead, cheeks, and chin. The lesions initially appeared as small bumps but have gradually increased in number. Over the past few weeks, some have become tender, especially before her menstrual cycle. She notes mild oiliness of the skin but denies using any new skincare products, cosmetics, or hair products. She has no history of similar eruptions as a child.

The Food and Drug Administration (FDA) has expanded the approval of Rapiblyk® (landiolol), an ultra-short-acting, selective beta-1-adenoreceptor antagonist, to include the treatment of supraventricular tachycardia (SVT) in pediatric patients, building upon its previous indication for adults with SVT. The approval for younger patients was based on data from the prospective, open-label, uncontrolled, phase 3 LANDI-PED study.

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for delgocitinib cream for the treatment of pediatric patients aged 12 to 17 years with moderate to severe chronic hand eczema (CHE). Delgocitinib is a Janus kinase (JAK) inhibitor that blocks the activation of the JAK-STAT (signal transducer and activator of transcription) pathway, which has been shown to play a key role in the pathophysiology of CHE.

HealthDay News — Ninety-day food supplementation is feasible and well accepted for individuals recently hospitalized with heart failure but did not lead to improvements in clinical outcomes, according to a study published online April 8 in JAMA Cardiology. Ambarish Pandey, MD, from the University of Texas Southwestern Medical Center in Dallas, and colleagues examined the association of food supplementation vs usual care with clinical outcomes in patients recently hospitalized with heart failure.

HealthDay News — The proportion of extensively drug-resistant (XDR) Shigella isolates in the United States increased from 2011-2015 to 2023, according to research published in the April 9 issue of the US Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

The Food and Drug Administration (FDA) has approved Filspari® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. The approval for FSGS was based on data from the randomized, double-blind, phase 3 DUPLEX trial (ClinicalTrials.gov Identifier: NCT03493685).

(HealthDay News) — Recommendations are presented for the prevention and management of pediatric atopic dermatitis (AD) in 2 guidelines issued by the American Academy of Dermatology and published online April 7 in the Journal of the American Academy of Dermatology.

HealthDay News — The Advisory Committee on Immunization Practices (ACIP) could soon have a new focus after officials changed the rules that determine who can serve on it. The updated rules were approved by Health Secretary Robert F. Kennedy Jr. and posted in a new charter outlining operation of the panel, which guides vaccine use in the US and advises the US Centers for Disease Control and Prevention (CDC). The changes expand who can serve on the committee and what topics it focuses on.